DOR-1 Polyclonal Antibody

OPRD1 (Opioid Receptor Delta 1) is a Protein Coding gene. Diseases associated with OPRD1 include morphine dependence and heroin dependence. Among its related pathways are cGMP-PKG signaling pathway andPeptide ligand-binding receptors. GO annotations related to this gene include G-protein coupled receptor activity and opioid receptor activity. An important paralog of this gene is GALR2.

The DOR-1 Polyclonal Antibody is a highly specific and reliable tool designed for the detection and analysis of the delta opioid receptor (DOR) protein. This antibody has been meticulously developed using advanced techniques to ensure exceptional sensitivity and specificity in various applications, including immunohistochemistry, western blotting, and immunofluorescence.

The DOR-1 Polyclonal Antibody exhibits outstanding performance in recognizing the DOR protein in a wide range of species, making it an ideal choice for researchers working with diverse biological samples. Its exceptional affinity and selectivity enable accurate and precise detection of the DOR protein, facilitating comprehensive investigations into its expression patterns, localization, and functional roles.

This antibody is manufactured under stringent quality control measures to guarantee batch-to-batch consistency and reproducibility. Its high affinity and low background ensure reliable and robust results, minimizing false positives and enhancing data reliability. The DOR-1 Polyclonal Antibody is supplied in a convenient and ready-to-use format, allowing for seamless integration into laboratory workflows.

With its exceptional performance and reliability, the DOR-1 Polyclonal Antibody is an indispensable tool for researchers studying the delta opioid receptor protein. Its versatility and accuracy make it an invaluable asset in elucidating the intricate mechanisms and functions of the DOR protein in various physiological and pathological processes. Trust in the DOR-1 Polyclonal Antibody to deliver precise and reproducible results, enabling groundbreaking discoveries in the field of opioid receptor research.